Circulating Cell-Free Tumour DNA in the Management of Cancer
AbstractWith the development of new sensitive molecular techniques, circulating cell-free tumour DNA containing mutations can be identified in the plasma of cancer patients. The applications of this technology may result in significant changes to the care and management of cancer patients. Whilst, currently, these “liquid biopsies” are used to supplement the histological diagnosis of cancer and metastatic disease, in the future these assays may replace the need for invasive procedures. Applications include the monitoring of tumour burden, the monitoring of minimal residual disease, monitoring of tumour heterogeneity, monitoring of molecular resistance and early diagnosis of tumours and metastatic disease. View Full-Text
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Francis, G.; Stein, S. Circulating Cell-Free Tumour DNA in the Management of Cancer. Int. J. Mol. Sci. 2015, 16, 14122-14142.
Francis G, Stein S. Circulating Cell-Free Tumour DNA in the Management of Cancer. International Journal of Molecular Sciences. 2015; 16(6):14122-14142.Chicago/Turabian Style
Francis, Glenn; Stein, Sandra. 2015. "Circulating Cell-Free Tumour DNA in the Management of Cancer." Int. J. Mol. Sci. 16, no. 6: 14122-14142.